A challenging environment

摘要

Predictions of slow growth, the development of new therapies, increased competition from low cost manufacturing operations and regulatory scrutiny around product quality and patient safety, dominate the horizon for the UK pharma and life science industry. Now is the time for drug manufacturers to seek out expert collaboration and embrace available automation technology and service solutions to support asset value, protect investments, reduce manufacturing costs, safeguard product quality and ensure patient safety.